UI Index

Pheochromocytoma mimicking an acute myocardial infarction.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

Menke-van der Houven van Oordt CW, Twickler TB, van Asperdt FG, Ackermans P, Timmers HJ, Hermus AR.
PMID: 17923879
Neth Heart J. 2007;15(7):248-51. doi: 10.1007/BF03085991.

We report a 42-year-old female who presented with retrosternal pain, dyspnoea and nausea. Electrocardiography suggested a recent anterior myocardial infarction. However, emergency coronary angiography showed normal blood flow through all the coronary arteries. Paroxysmal hypertension raised the suspicion of...

Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.

Oncotarget

Jansen RW, van Amstel P, Martens RM, Kooi IE, Wesseling P, de Langen AJ, Menke-Van der Houven van Oordt CW, Jansen BHE, Moll AC, Dorsman JC, Castelijns JA, de Graaf P, de Jong MC.
PMID: 29732009
Oncotarget. 2018 Apr 13;9(28):20134-20155. doi: 10.18632/oncotarget.24893. eCollection 2018 Apr 13.

With targeted treatments playing an increasing role in oncology, the need arises for fast non-invasive genotyping in clinical practice. Radiogenomics is a rapidly evolving field of research aimed at identifying imaging biomarkers useful for non-invasive genotyping. Radiogenomic genotyping has...

Diagnostic Performance of [.

Diagnostics (Basel, Switzerland)

Iqbal R, Mammatas LH, Aras T, Vogel WV, van de Brug T, Oprea-Lager DE, Verheul HMW, Hoekstra OS, Boellaard R, Menke-van der Houven van Oordt CW.
PMID: 34829301
Diagnostics (Basel). 2021 Oct 21;11(11). doi: 10.3390/diagnostics11111954.

Positron emission tomography using [

Potential and pitfalls of .

EJNMMI research

Huisman MC, Menke-van der Houven van Oordt CW, Zijlstra JM, Hoekstra OS, Boellaard R, van Dongen GAMS, Shah DK, Jauw YWS.
PMID: 34417917
EJNMMI Res. 2021 Aug 21;11(1):74. doi: 10.1186/s13550-021-00813-7.

CONCLUSION: The example for

[No title available]

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Mammatas LH, Yaqub M, Hendrikse NH, Hoekstra OS, Honeywell RJ, Schuit RC, Meijerink M, Schwarte LA, Peters GJ, Verheul HMW, Lammertsma AA, Menke-van der Houven van Oordt CW.
PMID: 33127619
J Nucl Med. 2021 Jul 01;62(7):934-940. doi: 10.2967/jnumed.120.251611. Epub 2020 Oct 30.

Sorafenib leads to clinical benefit in a subgroup of patients, whereas all are exposed to potential toxicity. Currently, no predictive biomarkers are available. The purpose of this study was to evaluate whether

[No title available]

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Mammatas LH, Yaqub M, Hendrikse NH, Hoekstra OS, Honeywell RJ, Schuit RC, Meijerink M, Schwarte LA, Peters GJ, Verheul HMW, Lammertsma AA, Menke-van der Houven van Oordt CW.
PMID: 33127619
J Nucl Med. 2021 Jul 01;62(7):934-940. doi: 10.2967/jnumed.120.251611. Epub 2020 Oct 30.

Sorafenib leads to clinical benefit in a subgroup of patients, whereas all are exposed to potential toxicity. Currently, no predictive biomarkers are available. The purpose of this study was to evaluate whether

Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology.

Cancers

Douma JAJ, Buffart LM, Sedhom R, Labots M, Menke-van der Houven van Oordt WC, Skardhamar M, De Felice A, Lee E, Dharmaraj D, Azad NS, Carducci MA, Verheul HMW.
PMID: 34064995
Cancers (Basel). 2021 May 11;13(10). doi: 10.3390/cancers13102304.

Despite stringent eligibility criteria for trial participation, early discontinuation often occurs in phase I trials. To better identify patients unlikely to benefit from phase I trials, we investigated predictors for early trial discontinuation. Data from 415 patients with solid...

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?.

Frontiers in pharmacology

Jauw YW, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, Huisman MC, van Dongen GA.
PMID: 27252651
Front Pharmacol. 2016 May 24;7:131. doi: 10.3389/fphar.2016.00131. eCollection 2016.

Selection of the right drug for the right patient is a promising approach to increase clinical benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo biodistribution and tumor targeting of mAbs to predict toxicity and efficacy...

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.

EJNMMI research

Jauw YWS, Huisman MC, Nayak TK, Vugts DJ, Christen R, Naegelen VM, Ruettinger D, Heil F, Lammertsma AA, Verheul HMW, Hoekstra OS, van Dongen GAMS, Menke-van der Houven van Oordt CW.
PMID: 29356983
EJNMMI Res. 2018 Jan 22;8(1):6. doi: 10.1186/s13550-018-0358-8.

BACKGROUND: Ideally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific,...

[No title available]

Oncotarget

van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, Nayak TK, Stokkel MPM, Mulder ER, Hoekstra OS, Vugts DJ, Van Dongen GAMS, Verheul HM, Evers S, Tessier JJL, Saro J, Schellens JHM, Menke-van der Houven van Oordt CW.
PMID: 29872502
Oncotarget. 2018 May 15;9(37):24737-24749. doi: 10.18632/oncotarget.25343. eCollection 2018 May 15.

Cergutuzumab amunaleukin (CEA-IL2v) is an immunocytokine directed against carcinoembryonic antigen (CEA) containing an IL2v-moiety with abolished IL-2 receptor (IL-2R) α binding. We describe the biodistribution and tumor accumulation of

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features.

Endocrinology, diabetes & metabolism case reports

Lima Ferreira J, Marques B, Menke-van der Houven van Oordt CW, de Herder WW, Brabander T, Hofland J.
PMID: 33982661
Endocrinol Diabetes Metab Case Rep. 2021 May 01;2021. doi: 10.1530/EDM-20-0172. Epub 2021 May 01.

SUMMARY: Middle ear adenomas with neuroendocrine features (ANEF) are rare, with an estimated 150 reported cases. They usually pursue an indolent clinical course. Four reported cases of middle ear ANEF with distant metastases were treated with surgery, external beam...

Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol.

Cancers

Geboers B, Timmer FEF, Ruarus AH, Pouw JEE, Schouten EAC, Bakker J, Puijk RS, Nieuwenhuizen S, Dijkstra M, van den Tol MP, de Vries JJJ, Oprea-Lager DE, Menke-van der Houven van Oordt CW, van der Vliet HJ, Wilmink JW, Scheffer HJ, de Gruijl TD, Meijerink MR, On Behalf Of The Dutch Pancreatic Cancer Group.
PMID: 34359801
Cancers (Basel). 2021 Aug 02;13(15). doi: 10.3390/cancers13153902.

Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique with the ability to generate a window for the establishment of systemic antitumor immunity. IRE transiently alters the tumor's immunosuppressive microenvironment while simultaneously generating antigen release, thereby instigating an...